BioSpace News Archive

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its first quarter financial results for the period ended March 31, 2024, before markets open on Wednesday, May 15, 2024.

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial preliminary results for the first quarter ended March 31, 2024.

Precedence Research Says, the global cell separation market size was valued at USD 10.92 billion in 2023 and it is increasing over USD 38.99 billion by 2033 with a CAGR of 13.54% from 2024 to 2033.

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024.

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced with great respect and sorrow the unexpected passing last night of the Company’s co-founder, President, Chairman and Chief Executive Officer, Rodney Varner, due to sudden complications after a courageous battle with cancer.

Innovent Biologics, Inc. announces that the Phase 3 clinical trial of mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, in Chinese subjects with type 2 diabetes met the primary endpoint.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming scientific and medical conferences.

Turnstone Biologics Corp. announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada.

Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor (ETBR), for the treatment of drug-resistant cancers in the iPROC platform study.

NeuShen Therapeutics (the “Company”) today announced the dosing of the first healthy volunteer in Australia in the Phase I first-in-human clinical trial of NS-136, a novel selective M4 receptor positive allosteric modulator (M4 PAM) designed for the treatment of schizophrenia and other conditions associated with psychosis.